Prevents pregnancy. ANDA 91454, held by Novast Labs. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 91454 (Larin Fe 1/20), held by Novast Labs, was first approved by FDA on Aug 26, 2013, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Microgestin Fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. 2
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 26, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Larin Fe 1/200.02MG;1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters